The Cystic Fibrosis Market to Witness Robust Growth Due to Increasing Cases of Cystic Fibrosis

Cystic fibrosis is a rare, progressive, life-threatening disease results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. If left untreated, it leads to severe digestive and respiratory problems as well as other complications such as infections and diabetes. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with cystic fibrosis around the world. As the number of cases of cystic fibrosis rises, so will the demand for cystic fibrosis treatment, thereby driving the growth of the cystic fibrosis market. Cystic fibrosis may also affect the liver, kidneys, pancreas, and intestine.

Some of the other signs and symptoms include sinus infections, fatty stool, infertility in males, poor growth, and guild of the fingers and toes. Different people may have diverse degrees of symptoms. It is mostly diagnosed by sweat test or genetic testing. Growth of the cystic fibrosis market, in North America, is driven by the increasing number of cases in the region.

According to the Cystic Fibrosis Foundation, more than 30,000 people in United States are living with cystic fibrosis. Moreover, around 1,000 new cases of cystic fibrosis are diagnosed each year, and more than half of the cystic fibrosis population is age 18 or older.

Coherent Market Insights celebrating 5th anniversary and offering 1000 USD off for all reports. Let’s celebrate with us.
Click for promo code: https://www.coherentmarketinsights.com/promo/buynow/236

This in turn is expected to increase the demand for cystic fibrosis treatment in this region, especially in the U.S. For example, in October 2019, the U.S, Food and Drug Administration (FDA) approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Moreover, in January 2021, FDA approved expanded indications for three medications for the treatment of patients with cystic fibrosis with specific mutations in the CFTR gene. Physical therapy, used to treat cystic fibrosis, helps reduce mucus formation and fights against infections of an organ.

Moreover, cystic fibrosis treatment includes the use of drugs such as Kalydeco, Pulmozyme, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation. Growth of the market is also driven by the increasing awareness among people regarding the severity of the disease and available treatment options, especially in developed countries. On the contrary, in some countries, new born are not tested for cystic fibrosis during birth and national registries are lacking in data, thereby hampering the growth of the cystic fibrosis market.

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/cystic-fibrosis-market-236

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

About Us:
Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. The company’s client base includes players from across various business verticals in over 47 countries globally. It takes pride in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and start-ups looking to establish a foothold in the market.

This release was published on openPR.